Maestro 1.1 Post-Market Registry
Launched by MOON SURGICAL · Oct 21, 2023
Trial Information
Current as of August 24, 2025
Recruiting
Keywords
ClinConnect Summary
The Maestro 1.1 Post-Market Registry is a study that looks at how well the Maestro Platform helps with laparoscopic surgery, which is a type of minimally invasive surgery where doctors make small cuts instead of larger ones. This trial is currently recruiting participants aged 18 years and older who are scheduled to have this type of surgery. If you or a loved one are considering laparoscopic surgery, you may be eligible to participate in this study.
Participants in this trial can expect to have their experiences with the Maestro Platform monitored during their surgery. The goal is to gather real-life data on how the platform performs in actual surgical settings. It's important to note that while most adults can join, there may be some individuals who are not eligible based on the doctor’s judgment. This study aims to improve surgical assistance tools for better outcomes in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants will be adults aged ≥ 18 years scheduled for laparoscopic surgery.
- Exclusion Criteria:
- • Participants might be excluded based on the investigator's discretion.
About Moon Surgical
Moon Surgical is an innovative medical technology company focused on advancing minimally invasive surgical solutions. By harnessing cutting-edge robotics and artificial intelligence, Moon Surgical aims to enhance surgical precision, improve patient outcomes, and streamline surgical workflows. The company is committed to transforming the surgical landscape through its pioneering products and clinical trials that seek to validate the safety and efficacy of its technologies. With a dedication to collaboration and excellence, Moon Surgical strives to empower surgeons and elevate the standard of care in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Denver, Colorado, United States
Jacksonville, Florida, United States
Strasbourg, , France
Saint Laurent Du Var, , France
Marseille, , France
Besançon, , France
Fort Myers, Florida, United States
Jacksonville, Florida, United States
Orlando, Florida, United States
Cedar Park, Texas, United States
Auderghem, , Belgium
Mougin, Alpes Maritimes, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported